featured
ASCO: Immunotherapy Beneficial in Advanced Bladder Cancer
About a quarter of older patients deemed too frail for chemotherapy responded to atezolizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: